Doerthe Eckert
AbbVie (Germany)(DE)Klinikum Ludwigshafen(DE)
Publications by Year
Research Areas
Microscopic Colitis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus Research, Chronic Lymphocytic Leukemia Research, Hepatitis C virus research
Most-Cited Works
- → Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease(2015)98 cited
- → Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia(2016)62 cited
- → Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy(2022)46 cited
- → Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis(2019)29 cited
- → Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients(2022)16 cited
- → Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection(2016)16 cited
- → Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials(2016)15 cited
- → A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients(2021)15 cited
- → Population pharmacokinetic and exposure‐response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis(2023)13 cited
- → Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis(2013)12 cited